PK, PD and interactions: the new scenario with JAK inhibitors and S1P Receptor Modulators, two classes of small molecule drugs, in IBD.
Fiche publication
Date publication
juin 2020
Journal
Expert review of gastroenterology & hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Gilardi D, Gabbiadini R, Allocca M, Correale C, Fiorino G, Furfaro F, Zilli A, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
Inflammatory bowel disease (IBD) are immune-mediated chronic inflammatory disorders of the gastrointestinal tract whose pathogenesis is not yet fully understood. Despite the advent of biological agents, there are still unmet needs for IBD patients, due to suboptimal rate of sustained remission achieved. Small molecule drugs (SMDs), the next generation of selective drugs in IBD, show promising results in ongoing trials.
Mots clés
Cytochrome P450s, Drug-drug interactions, Janus Kinase inhibitors, Pharmacodynamics, Pharmacokinetics, Small Molecule Drugs, Sphingosine-1-Phosphate Receptor Modulators, inflammatory bowel disease
Référence
Expert Rev Gastroenterol Hepatol. 2020 Jun 22;: